Mallinckrodt PLC (NYSE:MNK) versus Its Rivals Head to Head Review

Mallinckrodt PLC (NYSE: MNK) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Mallinckrodt PLC to similar companies based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation.


This table compares Mallinckrodt PLC and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mallinckrodt PLC 12.64% 15.28% 5.20%
Mallinckrodt PLC Competitors -540.60% -41.61% -24.68%

Earnings and Valuation

This table compares Mallinckrodt PLC and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Mallinckrodt PLC $3.27 billion $666.60 million 7.49
Mallinckrodt PLC Competitors $2.40 billion $905.93 million -0.10

Mallinckrodt PLC has higher revenue, but lower earnings than its peers. Mallinckrodt PLC is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Mallinckrodt PLC has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Mallinckrodt PLC’s peers have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Mallinckrodt PLC and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mallinckrodt PLC 0 4 13 0 2.76
Mallinckrodt PLC Competitors 67 312 962 27 2.69

Mallinckrodt PLC currently has a consensus target price of $59.97, suggesting a potential upside of 95.28%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 23.17%. Given Mallinckrodt PLC’s stronger consensus rating and higher probable upside, research analysts plainly believe Mallinckrodt PLC is more favorable than its peers.

Institutional & Insider Ownership

97.5% of Mallinckrodt PLC shares are held by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 0.8% of Mallinckrodt PLC shares are held by insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Mallinckrodt PLC beats its peers on 10 of the 13 factors compared.

About Mallinckrodt PLC

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with's FREE daily email newsletter.

Leave a Reply